Because topical antibiotic treatment has had a limited effect in previous controlled trials against trachoma, treatment with oral erythromycin was compared with topical tetracycline in 6-8-year-old children in southern Tunisia who had potentially blinding active trachoma. A total of 169 children were divided into two groups that were carefully matched for age, sex, locality, and intensity of disease. Oral erythromycin ethyl succinate in a paediatric dosage form was administered to one group and topical 1% tetracycline ointment to the other group, twice daily, six days a week for three weeks. The two treatments were equivalent in effectiveness and resulted in a substantial decrease in disease intensity and a marked reduction in chlamydial infection detected in conjunctival smears. To maintain blood levels of antibiotics known to be effective in the treatment of chlamydial infections with a dosage schedule possible in a trachoma control programme, one of the long-acting tetracyclines (doxycycline or minocycline) might be considered. Such systemic chemotherapy should be limited to selective treatment of individuals who can be adequately monitored.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2536005 | PMC |
Rev Med Suisse
January 2025
Service de dermatologie et vénéréologie, Hôpitaux universitaires de Genève, 1211 Genève 14.
This article focuses on two key innovations in dermatology: post-exposure prophylaxis for sexually transmitted infections (STIs) and new therapeutic options for inflammatory skin diseases. New European and American guidelines for doxycycline post-exposure prophylaxis (Doxy PEP) aim to prevent STIs in men who have sex with men (MSM) and individuals on HIV pre-exposure prophylaxis (PrEP). Doxy PEP is effective against syphilis and chlamydia, but its efficacy is limited by growing gonorrhea resistance.
View Article and Find Full Text PDFIntroduction: EGFR tyrosine kinase inhibitor (TKI)-induced rash can be alleviated with tetracyclines (TCN) and topical corticosteroids (TCS), whereas drugs for acid-related disorders (DARD) can affect EGFR TKI absorption. The present study investigated the concomitant use of TCNs, TCSs, and DARDs with EGFR-TKIs in non-small cell lung cancer (NSCLC) and whether these affect patient outcomes.
Methods: We retrospectively collected data from all patients (n=1498) who had purchased for EGFR TKIs (erlotinib, gefitinib, and afatinib) in Finland between 2011-2020.
Carbohydr Polym
February 2025
Department of Biotechnology, Yonsei University, 50 Yonsei-ro, Seoul 03722, Republic of Korea; Juvic Inc., 208Ho, 272, Digital-ro, Guro-gu, Seoul 08389, Republic of Korea. Electronic address:
Periodontitis is a prevalent inflammatory disease that affects tooth-supporting tissues and is induced by complex polymicrobial dental plaques. Prior treatments, including topical antibiotic ointments, have faced difficulties in tissue permeability issues. Although dissolving microneedle (DMN) has been proposed as a painless and highly efficient transdermal drug delivery system to resolve this challenge, minocycline, widely used for the treatment of periodontitis, is light-sensitive, making it challenging to maintain its stability using conventional fabrication methods.
View Article and Find Full Text PDFPolim Med
December 2024
Department of Physical Chemistry and Biophysics, Faculty of Pharmacy, Wroclaw Medical University, Poland.
Background: Acne vulgaris is a common inflammatory skin condition affecting almost 85% of the adolescent and young adult population. The etiopathogenesis of this dermatosis involves an imbalance in the skin microbiome, leading to inflammation of both the skin and hair follicles.
Objectives: The aim of this study was to develop topical anti-acne formulations with increased therapeutic efficacy and reduced risk of developing antibiotic resistance.
Dermatol Clin
January 2025
Department of Dermatology, Brigham and Women's Hospital, 41 Avenue Louis Pasteur, 317A, Boston, MA 02115, USA. Electronic address:
Although many treatments are available for acne, these can be limited by lack of effectiveness, patient tolerance and adherence, and accessibility. This review provides a comprehensive summary of the latest developments in acne management, exploring a range of topical, systemic, and procedural treatments. The mechanisms of action, pivotal trial data, and potential role in clinical practice are reviewed for emerging therapies such as 1726 nm laser, sarecycline, clascoterone, trifarotene, minocycline foam, and fixed-dose combination topicals.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!